Class I and II Histone Deacetylase Inhibitor LBH589 Promotes Endocrine Differentiation in Bone Marrow Derived Human Mesenchymal Stem Cells and Suppresses Uncontrolled Proliferation
In conclusion, we deliver evidence that a combined class I and II histone deacetylase inhibition is able to modulate the transcripts of differentiation markers of mesenchymal stem cells. The treatment holds the capability to facilitate endocrine differentiation in future approaches to replace endocrine cells by stem cell therapy. [...] © Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents | Abstract | Full text
Source: Experimental and Clinical Endocrinology and Diabetes - Category: Endocrinology Authors: Schr öder, Christoph Khatri, Rahul Petry, Sebastian Friedrich Linn, Thomas Tags: Article Source Type: research
More News: Autoimmune Disease | Cancer | Cancer & Oncology | Diabetes | Diabetes Mellitus | Endocrinology | Genetics | Insulin | Pancreas | Pancreatic Cancer | Stem Cell Therapy | Stem Cells | Study | Transplants